Septerna, Inc. Common Stock
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 … Read more
Septerna, Inc. Common Stock (SEPN) - Net Assets
Latest net assets as of September 2025: $388.73 Million USD
Based on the latest financial reports, Septerna, Inc. Common Stock (SEPN) has net assets worth $388.73 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($606.65 Million) and total liabilities ($217.92 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $388.73 Million |
| % of Total Assets | 64.08% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Septerna, Inc. Common Stock - Net Assets Trend (2022–2024)
This chart illustrates how Septerna, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Septerna, Inc. Common Stock (2022–2024)
The table below shows the annual net assets of Septerna, Inc. Common Stock from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $420.05 Million | +1194.61% |
| 2023-12-31 | $-38.37 Million | +13.18% |
| 2022-12-31 | $-44.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Septerna, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6761800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $44.00K | 0.01% |
| Other Comprehensive Income | $56.00K | 0.01% |
| Other Components | $538.32 Million | 128.16% |
| Total Equity | $420.05 Million | 100.00% |
Septerna, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Septerna, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
bpost SA/NV
PINK:BPOSF
|
$472.00 Million |
|
Hubei Jiuzhiyang Infrared System Co Ltd
SHE:300516
|
$472.25 Million |
|
FUJI KYUKO CO. LTD
F:8V7
|
$472.27 Million |
|
Xinjiang Yilite Industry Co Ltd
SHG:600197
|
$472.35 Million |
|
Hangzhou DPtech Technologies Co Ltd
SHE:300768
|
$471.86 Million |
|
Dexus Industria REIT
AU:DXI
|
$471.85 Million |
|
Zhejiang Yongjin Metal Technology Co Ltd
SHG:603995
|
$471.63 Million |
|
Central Plaza Hotel Public Company Limited
BK:CENTEL
|
$471.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Septerna, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -38,374,000 to 420,047,000, a change of 458,421,000.
- Net loss of 71,798,000 reduced equity.
- Share repurchases of 1,000 reduced equity.
- New share issuances of 377,730,000 increased equity.
- Other comprehensive income increased equity by 56,000.
- Other factors increased equity by 152,434,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-71.80 Million | -17.09% |
| Share Repurchases | $1.00K | -0.0% |
| Share Issuances | $377.73 Million | +89.93% |
| Other Comprehensive Income | $56.00K | +0.01% |
| Other Changes | $152.43 Million | +36.29% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Septerna, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.59x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $-2.27 | $25.17 | x |
| 2023-12-31 | $-1.97 | $25.17 | x |
| 2024-12-31 | $42.47 | $25.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Septerna, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6678.88%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-17.09%) is below the historical average (-5.70%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.26 Million |
| 2023 | 0.00% | 2768.21% | 0.00x | 0.00x | $8.02 Million |
| 2024 | -17.09% | -6678.88% | 0.00x | 1.09x | $-113.80 Million |
Industry Comparison
This section compares Septerna, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Septerna, Inc. Common Stock (SEPN) | $388.73 Million | 0.00% | 0.56x | $471.92 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |